3 results
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMORecruiting
To investigate efficacy of neoadjuvant axitinib and avelumab in patients with localized renal cell carcinoma with moderate to high risk of recurrence .
Approved WMORecruiting
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…